ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.80.

A number of brokerages recently weighed in on PRQR. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Oppenheimer initiated coverage on shares of ProQR Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $9.00 target price on the stock.

Institutional Trading of ProQR Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of PRQR. Aberdeen Group plc lifted its position in shares of ProQR Therapeutics by 28.4% in the fourth quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock valued at $5,960,000 after buying an additional 651,853 shares during the last quarter. Ikarian Capital LLC increased its holdings in shares of ProQR Therapeutics by 67.2% during the 4th quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after acquiring an additional 600,000 shares during the last quarter. Privium Fund Management B.V. increased its holdings in shares of ProQR Therapeutics by 7.2% during the 4th quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock worth $10,823,000 after acquiring an additional 359,475 shares during the last quarter. Citadel Advisors LLC raised its stake in ProQR Therapeutics by 73.2% in the 3rd quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock valued at $1,399,000 after acquiring an additional 277,749 shares during the period. Finally, Affinity Asset Advisors LLC raised its stake in ProQR Therapeutics by 6.5% in the 2nd quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock valued at $7,139,000 after acquiring an additional 215,000 shares during the period. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Up 7.3%

PRQR stock opened at $1.62 on Wednesday. The company has a market cap of $170.68 million, a price-to-earnings ratio of -3.52 and a beta of 0.21. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $3.10. The business has a 50 day moving average price of $1.59 and a two-hundred day moving average price of $2.00.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The company had revenue of $5.53 million for the quarter, compared to the consensus estimate of $6.12 million. ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%. On average, equities research analysts anticipate that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.